Alzheimer’s blood tests raise demand and doubts

Interest in Alzheimer’s blood tests is rising sharply among patients — but many doctors remain cautious about their real-world value.

A recent survey of nearly 600 adults found that 85% would take the test if recommended by a physician. Yet behind that enthusiasm lies a more complex reality: the science is still evolving, and the clinical benefits remain uncertain.

How Alzheimer’s blood tests work

Most Alzheimer’s blood tests measure levels of proteins such as amyloid and tau, which are linked to the disease and can accumulate in the brain decades before symptoms appear.

While this offers the promise of early detection, it does not guarantee that a person will develop the condition.

Experts warn that:

• Some people with positive results never develop Alzheimer’s
• Biomarkers may appear as part of normal aging
• Test results can vary depending on the method used

That uncertainty has fueled ongoing debate in the medical community.

High interest, but emotional impact

The demand for testing appears driven largely by anxiety and the desire for clarity.

According to the survey published in Alzheimer’s & Dementia:

• Nearly 3 in 4 patients expect distress after a positive result
• Many still say they would take action to improve brain health
• Most respondents had never heard of the test before

Andrea Russell, a psychologist at Northwestern University Feinberg School of Medicine, said the results reflect what she sees in clinical practice.

“People want to understand what’s happening to them,” she said — even if the answers are uncertain.

Doctors question clinical usefulness

For physicians, the biggest issue is not just accuracy — but what comes next.

There is currently no cure for Alzheimer’s disease, and available treatments offer limited benefits. Drugs such as Leqembi and Kisunla may slow progression, but they also carry risks, including brain swelling and bleeding.

Dr. Alberto Espay, a neurologist at University of Cincinnati College of Medicine, said early detection only matters if it leads to better outcomes.

“There is zero evidence that people at the earliest stages would benefit from anything we have,” he said.

What regulators currently allow

The U.S. Food and Drug Administration has cleared two Alzheimer’s blood tests — but only for patients already showing symptoms.

These tests:

• Are not standalone diagnostic tools
• Must be used alongside imaging, such as PET scans
• Carry risks of false positives and false negatives

Despite that, at least 25 blood tests are already available globally, with more in development.

Promise vs. limitations

Some researchers see clear potential in how the tests could be used:

1. Screening tool – identifying patients for further testing
2. Monitoring treatment – tracking changes over time
3. Future diagnosis – potentially replacing more invasive tests

Dr. Ronald Petersen of Mayo Clinic said accuracy has improved significantly, but inconsistencies remain.

“The jury is still out,” he said.

The bigger ethical question

Even if the tests become more reliable, a deeper issue remains:
Should people know their risk if little can be done about it?

For some patients, early knowledge may provide:

• A sense of control
• Time to plan for the future
• Motivation to adopt healthier habits

For others, it may lead to anxiety without clear medical benefit.

What comes next

Researchers say Alzheimer’s blood tests could eventually transform how the disease is detected and managed — especially if treatments improve.

For now, however, the technology sits in a gray zone between scientific promise and clinical uncertainty.

And as demand grows, doctors face a difficult balance: offering answers patients want, while acknowledging how incomplete those answers still are.